Jim Simons Leap Therapeutics, Inc. Transaction History

Renaissance Technologies LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.29 - $0.72 $136,445 - $338,760	-470,500 Reduced 50.83%	455,200 $155,000
Q4 2022 Feb 13, 2023	BUY	$0.42 - $9.18 $224,448 - $4.91 Million	534,400 Added 136.57%	925,700 $417,000
Q3 2022 Nov 14, 2022	SELL	$0.92 - $9.3 $211,158 - $2.13 Million	-229,520 Reduced 36.97%	391,300 $344,000
Q2 2022 Aug 12, 2022	BUY	$0.96 - $1.91 $595,987 - $1.19 Million	620,820 New	620,820 $714,000
Q1 2022 May 13, 2022	SELL	$1.6 - $3.35 $95,200 - $199,325	-59,500 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$2.08 - $3.65 $1.9 Million - $3.34 Million	-913,700 Reduced 93.89%	59,500 $193,000
Q3 2021 Nov 12, 2021	BUY	$1.35 - $4.01 $1.07 Million - $3.18 Million	791,915 Added 436.83%	973,200 $3.9 Million
Q2 2021 Aug 13, 2021	BUY	$1.48 - $1.92 $223,013 - $289,315	150,685 Added 492.43%	181,285 $297,000
Q1 2021 May 13, 2021	SELL	$1.82 - $3.01 $545,818 - $902,698	-299,900 Reduced 90.74%	30,600 $58,000
Q4 2020 Feb 10, 2021	SELL	$1.49 - $2.37 $548,618 - $872,634	-368,200 Reduced 52.7%	330,500 $744,000
Q3 2020 Nov 13, 2020	BUY	$1.68 - $2.17 $371,619 - $480,008	221,202 Added 46.33%	698,700 $1.38 Million
Q2 2020 Aug 13, 2020	BUY	$1.39 - $2.84 $423,528 - $865,339	304,697 Added 176.33%	477,498 $998,000
Q1 2020 May 14, 2020	BUY	$1.06 - $2.94 $183,169 - $508,034	172,801 New	172,801 $273,000
Q1 2019 May 14, 2019	SELL	$1.39 - $3.07 $226,450 - $500,145	-162,914 Closed	0 $0
Q4 2018 Feb 13, 2019	BUY	$1.92 - $7.94 $312,794 - $1.29 Million	162,914 New	162,914 $326,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $263M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.